How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,322 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients

Posted : April 5, 2018 See Sponsor: Pooja Budhiraja, MD Information provided by (Responsible Party): Pooja Budhiraja, MD, University of Kansas Medical Center Study Details Study Description Go to Brief Summary: The purpose of this study is to learn if using a Entocort (budesonide) to treat diarrhea will be effective and safe for kidney transplant patients, allowing them to continue with MPA medication. Condition or disease Intervention/treatment Phase Diarrhea Drug: Entocort Drug: Placebos Phase 2 (...) Measures Go to Primary Outcome Measures : Complete remission of diarrhea [ Time Frame: Week 8 ] Measured using symptom diary. Complete remission (CR) is defined as a mean of <3 stools/day and a mean of <1 watery stool per day without use of anti-diarrheal drugs. Secondary Outcome Measures : Change in Gastrointestinal Symptom Rating Scale (GSRS) [ Time Frame: Change from Baseline to Week 8 ] GSRS is a 15-item instrument designed to assess the symptoms associated with common GI disorders. The GSRS

2016 Clinical Trials

62. Bacillus Particles Prevent Children Antibiotics Associated Diarrhea

Prevent Children Antibiotics Associated Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02993419 Recruitment Status : Unknown Verified December 2016 by Jiangsu Famous Medical Technology Co., Ltd.. Recruitment status was: Not yet recruiting First Posted : December 15, 2016 Last Update Posted (...) years old,by observing the given antibiotics at the same time with the whole bowel raw or placebo, prevent the happening of the antibiotic associated diarrhea, evaluate the whole bowel prevention clinical efficacy and safety of AAD. Outcome measures MAIN OUTCOME MEASURES: The incidence of diarrhea (stool frequency and character daily rates), the duration of diarrhea, the degree of diarrhea occur. Secondary outcomes: intestinal flora and relevant metabolites, micro-environmental changes. Study Design

2016 Clinical Trials

63. Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record (...) Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

2016 Clinical Trials

64. HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens (Full text)

or paclitaxel (THP) or trastuzumab, pertuzumab, docetaxel, and carboplatin (TCHP) will be randomized to receive crofelemer or no medication for diarrhea prophylaxis. The primary endpoint is incidence of all grade diarrhea for ≥ 2 consecutive days during cycles 1 to 2 of THP or TCHP. Secondary endpoints include overall incidence, duration, and severity of diarrhea; time to onset of diarrhea; use of other anti-diarrheal medications; stool frequency and consistency; and quality of life. HALT-D will provide (...) HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens Approximately 40% to 80% of patients receiving pertuzumab-directed therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer will develop chemotherapy-induced diarrhea (CID). Loperamide and octreotide are frequently used to treat CID after diarrhea occurs, but neither is used prophylactically or targets the underlying

2016 Clinical breast cancer Controlled trial quality: uncertain PubMed abstract

65. Medical Treatment for Microscopic Colitis: A Community Hospital’s Experience (Full text)

Medical Treatment for Microscopic Colitis: A Community Hospital’s Experience Lymphocytic colitis (LC) is a chronic disorder characterized by watery diarrhea. This study sought to evaluate if LC recurs after therapy, and the time frame in which this occurs. Secondary objectives included length and type of therapy, drug-free intervals, and reasons for drug discontinuation.A retrospective chart review between January 1, 2008 and October 30, 2015 of patients with biopsy-confirmed lymphocytic (...) , collagenous, or microscopic colitis was conducted. Patient-reported average bowel movements/day were reviewed. Demographic data, dates of colonoscopy, follow-up, type and dose of medications used, and therapy start/stop dates were reviewed.Patients presenting with colonoscopic documented LC (n = 114) were predominantly female (88%), Caucasian (97%), with mean bowel movements/day of five. A total of 58/114 (51%) patients were placed on a therapy. Patients taking budesonide saw bowel movements/day reduced

2018 Gastroenterology research PubMed abstract

66. Branched Chain Amino Acids Ratio in Medical Foods

Branched Chain Amino Acids Ratio in Medical Foods Branched Chain Amino Acids Ratio in Medical Foods - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Branched Chain Amino Acids Ratio in Medical Foods (...) by (Responsible Party): Rajavel Elango, PhD, University of British Columbia Study Details Study Description Go to Brief Summary: This study will evaluate the branched-chain amino acids (BCAA) ratio in the medical foods formulated for Methylmalonic and Propionic Acidemias (MMA/PROP) patients. We will recruit 6 healthy children between 6-10y (3 boys and 3 girls). They will be given amino acid-based shakes and protein free cookies. Using a minimally invasive stable isotope based technique, we will be able

2018 Clinical Trials

67. Bladder Antimuscarinic Medication and Accidental Bowel Leakage

: Severe constipation, fecal impaction or overflow fecal incontinence Inflammatory bowel disease, colorectal CA, spinal cord injury, multiple sclerosis, stroke, myasthenia gravis Infectious diarrhea Bothersome SUI (defined as "moderately" or greater bother on UDI-3) Patients planning to undergo surgery during study period Patients who are pregnant or intending to become pregnant during the study period Patients with contraindications to antimuscarinic medications (ie. closed angle glaucoma) Patients (...) Bladder Antimuscarinic Medication and Accidental Bowel Leakage Bladder Antimuscarinic Medication and Accidental Bowel Leakage - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bladder Antimuscarinic

2018 Clinical Trials

68. Inulin-Type Fructan Supplementation of 3 to 6 Year-Old Children Is Associated with Higher Fecal Bifidobacterium Concentrations and Fewer Febrile Episodes Requiring Medical Attention. (Full text)

Inulin-Type Fructan Supplementation of 3 to 6 Year-Old Children Is Associated with Higher Fecal Bifidobacterium Concentrations and Fewer Febrile Episodes Requiring Medical Attention. Inulin-type fructans used in formula have been shown to promote microbiota composition and stool consistency closer to those of breastfed infants and to have beneficial effects on fever occurrence, diarrhea, and incidence of infections requiring antibiotic treatment in infants.The primary study aim was to explore (...) whether prophylactic supplementation with prebiotic fructans is able to influence the frequency of infectious diseases in kindergarten children during a winter period. A secondary objective was to ascertain the effect on the intestinal microbiota.142 boys and 128 girls aged 3-6 y were randomly allocated to consume 6 g/d fructans or maltodextrin for 24 wk. At baseline, stool samples were collected for microbiota analysis and anthropometric measurements were made. During the intervention period

2018 Journal of Nutrition Controlled trial quality: uncertain PubMed abstract

69. Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT

burden and nausea were barriers) First Posted : December 2, 2015 Results First Posted : June 14, 2017 Last Update Posted : June 14, 2017 Sponsor: Mayo Clinic Collaborator: Entera Health, Inc Information provided by (Responsible Party): Michael Camilleri, Mayo Clinic Study Details Study Description Go to Brief Summary: For patients who receive a hematopoietic cell transplant (HCT), there is a risk of developing a diarrhea secondary to the chemotherapy which we give. Diarrhea is usually harmless (...) the Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the "ideal stools" especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends

2015 Clinical Trials

70. Probiotics in the Reduction of Antibiotic Associated Diarrhea

. Outcome Measures Go to Primary Outcome Measures : Antibiotic Associated Diarrhea [ Time Frame: 21 days after starting study treatment ] Subjects will be asked to keep a diary for 20 days after starting study treatment and will be contacted by a nurse approximately 21 days after starting study treatment Secondary Outcome Measures : Length of stay [ Time Frame: during hospitalization up to 4 weeks ] Mortality [ Time Frame: During hospitalization up to 4 weeks ] Healthcare costs [ Time Frame: During (...) coherency to understand consent Active Diarrhea at admission Non-controlled intestinal disease Documented positive C. difficile infection within the 3 months before enrollment Antibiotic use at hospital admission Immunosuppressive therapy Pregnancy Allergic to ingredients in Florajen-3 Allergic to ingredients in placebo Immunocompromised state including: HIV with a low CD4 count Active malignancy receiving chemotherapy Medications including long-term steroids (>2 weeks), and disease modifying biologic

2015 Clinical Trials

71. Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome

Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02565654 Recruitment Status : Unknown Verified June 2015 by XiaojunZhuang, First Affiliated Hospital, Sun Yat-Sen University. Recruitment status was: Not yet recruiting First

2015 Clinical Trials

72. Effects of Bifidobacterium Longum BB536 on Incidence of Acute Diarrhea and/or Respiratory- Related Illnesses in Children

Outcome Measures : Absentia between BB536 vs. Placebo children in daycare centers due to diarrhea and/or respiratory-related illnesses [ Time Frame: 10 monhts ] Severity of diarrhea between BB536 vs. Placebo children [ Time Frame: 10 months ] Severity of respiratory-related illnesses between BB536 vs. Placebo children [ Time Frame: 10 months ] Secondary Outcome Measures : Fecal microbiota profiles of BB536 vs. Placebo children [ Time Frame: 10 months ] Eligibility Criteria Go to Information from (...) Effects of Bifidobacterium Longum BB536 on Incidence of Acute Diarrhea and/or Respiratory- Related Illnesses in Children Effects of Bifidobacterium Longum BB536 on Incidence of Acute Diarrhea and/or Respiratory- Related Illnesses in Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2015 Clinical Trials

73. Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea

: Uniformed Services University of the Health Sciences Collaborators: Naval Medical Research Center Ministry of Defence, United Kingdom Information provided by (Responsible Party): Ramiro Gutierrez, Naval Medical Research Center Study Details Study Description Go to Brief Summary: The purpose of this study is to develop evidence on the relative efficacy of 2 rifaximin chemoprophylaxis regimens for the prevention of Travelers' Diarrhea (TD) in a deployed setting. An additional purpose is to explore (...) aid [ Time Frame: 24hr ] Secondary Outcome Measures : Efficacy as determined by use of a symptom memory aid. [ Time Frame: For a duration of prophylaxis which will be on average 3-4 weeks or a maximum of 6 weeks ] Proportion of subjects in each treatment group with TD, with mild diarrhea, with TD associated with isolation of a pathogen and pathogen type, total diarrhea days, work days and performance loss due to diarrhea, comparison of incidence of TD Solicited adverse events as collected from

2015 Clinical Trials

74. Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)

Measures Go to Primary Outcome Measures : Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea during the first cycle of chemotherapy in the target population [ Time Frame: 15 days ] Secondary Outcome Measures : Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea during the first cycle of chemotherapy in the additional population [ Time Frame: 15 days ] Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea during the second and third cycle of chemotherapy - target (...) of first, second and third cycle of chemotherapy ] Proportion of patients: who required i.v. fluids due to CID, who required changes to the primary therapy due to CID, who used rescue medication (i.e. medication used for treatment of diarrhea) by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ] Proportion of patients having a maximum Grade ≥ 2 diarrhea - shift from Cycle 1 to Cycle 2 and from Cycle 2 to Cycle 3 - target population

2015 Clinical Trials

75. Comparative Evaluation of Herbal and Allopathic Drugs for the Treatment of Chronic Diarrhea

[ Time Frame: 5 days ] The primary efficacy criterion will be the frequency and consistency of diarrhea in hours, from the first treatment dose to recovery. It will be evaluated through stool D/R. Stool D/R described the consistency, frequency and other important features of stool. Semisolid stool consistency with 1-2/day will be considered significant. Secondary Outcome Measures : Improvement in clinical symptoms such as abdominal pain, abdominal distension, etc will be secondary outcome measures (...) Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Male or female adults between the age of 18-60 years who were suffering from diarrhea of presumed infectious origin and willing to participate were eligible for inclusion in the study. Exclusion Criteria: Exclusion criteria were the presence of chronic Iatrogenic, or bloody diarrhea, having received antibiotic treatment for other medical or surgical problems Having a history of renal or hepatic dysfunction Having

2015 Clinical Trials

76. Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir

days). ] The overall incidence of diarrhea, represented as a percentage of patients, that develop diarrhea during the course of their enrollment in the study (an average of 35 days). Secondary Outcome Measures : Incidence of Clostridium difficile infection among the three randomized study groups over time [ Time Frame: Assessed at any point during a patient's enrollment in the study (average of 35 days) when clinical symptoms require a C. difficile test per standard of care. Individual patients (...) Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2015 Clinical Trials

77. Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children

]) and no other copathogen. Secondary Outcome Measures : Time to first event of diarrhea due to ST-only ETEC expressing a vaccine-shared CF (ST-VCF-ETEC) as defined below, and no other copathogen.. [ Time Frame: 365-day period starting 14 days after the third vaccination ] Time to first event of diarrhea associated with excretion of ST-VCF-ETEC (defined as ETEC expressing ST-only plus any vaccine-shared colonization factor [i.e., CFA/I, CS1, CS2, CS3, CS4, and/or CS5]) and no other copathogen. All events (...) table for investigator information Principal Investigator: Stephen Savarino, MD, MPH Naval Medical Research Center More Information Go to Layout table for additonal information Responsible Party: U.S. Army Medical Research and Materiel Command ClinicalTrials.gov Identifier: Other Study ID Numbers: HSRRB A-7965 First Posted: September 22, 2015 Last Update Posted: October 12, 2015 Last Verified: October 2015 Additional relevant MeSH terms: Layout table for MeSH terms Diarrhea Signs and Symptoms

2015 Clinical Trials

78. Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome

Information provided by (Responsible Party): Chengdu University of Traditional Chinese Medicine Study Details Study Description Go to Brief Summary: The purpose of this study is to test the efficacy and safety of a traditional Chinese medication Tong-Xie-Yao-Fang for patients with diarrhea-predominant irritable bowel Syndrome (IBS-D). Condition or disease Intervention/treatment Phase Diarrhea-predominant Irritable Bowel Syndrome Drug: Tong-Xie-Yao-Fang Drug: Placebo Phase 2 Phase 3 Detailed Description (...) Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Tong

2015 Clinical Trials

79. Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence

. For participants who withdraw from the trial due to reasons other than complete resolution of the symptoms of diarrhea, TTLUS is defined as the number of hours from the start of the trial to the time of withdrawal. Time to Complete Amelioration of Abdominal Discomfort [ Time Frame: 48 hours ] The time over which abdominal discomfort caused by gastrointestinal gas accumulation is completely resolved. Secondary Outcome Measures : Number of Participants With Complete Remission of Diarrhea [ Time Frame: Up to 48 (...) Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail

2015 Clinical Trials

80. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics

Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics 1 © American College of Medical Genetics and Genomics ACMG St And ArdS And GuidelineS PURPOSE This guideline is intended as an educational resource. It high- lights current practices and therapeutic approaches to the diagnosis and management of GSD I and its early and long- term complications. GENERAL BACKGROUND History In 1929, von Gierke described glycogen (...) storage disease type I (GSD I) after reviewing the autopsy reports of two children whose livers and kidneys contained excessive amounts of Submitted 12 August 2014; accepted 12 August 2014; advance online publication 6 November 2014. doi:10.1038/gim.2014.128 Genet Med 00 00 2014 Genetics in Medicine 10.1038/gim.2014.128 ACMG Standards and Guidelines 00 00 12August2014 12August2014 © American College of Medical Genetics and Genomics 6November2014 Purpose: Glycogen storage disease type I (GSD I

2014 American College of Medical Genetics and Genomics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>